Slide 1: FY25 Results Presentation
For personal use only FY25 Results Presentation September 2025 CEO Peter Davey CFO Andrew Allibon
Slide 2: Clover Corp – at a glance
Clover Corp – at a glance For personal use only Global leader Markets Manufacturing footprint in microencapsulated omega-3 Infant nutrition oils for infant formula and Australia – Refinery and R&D hub Functional food & beverage functional foods New Zealand – Powder production facility Pharmaceutical
Slide 3: FY25 Results – strong growth across all metrics
FY25 Results – strong growth across all metrics For personal use only Revenue growth of 38% on pcp $86m $12.1m Revenue EBITDA EBITDA growth of 214% on pcp $8.7m $7.0m Strong balance sheet / debt reduction Cash NPAT NPAT growth of 382 % on pcp $0.01 p/ share Final Dividend Clover Corp | Results Prese
Slide 4: FY25 Operational highlights
FY25 Operational highlights Ecuador For personal use only • Crude oil production with deliveries • Record revenue, with new having commenced in November customers significantly 2024. increasing order numbers. • Facility now supplies ~30% of Clover’s tuna oil requirements. • Existing infant formula c
Slide 5: FY25 Drivers of growth
FY25 Drivers of growth 1 2 3 For personal use only Market recovery & expansion Capital strength Operational discipline • Improving outlook in core markets. • USD-denominated cash holdings • Tighter inventory control aligned • Western manufacturers grow share and receivables underpin Clover’s with de
Slide 6: Financials
For personal use only Financials 6
Slide 7: Full year 2025 Profit and Loss
Full year 2025 Profit and Loss Reported Reported • FY25 delivered strong revenue growth, Movement For personal use only AUD Million 31 Jul 2025 31 Jul 2024 underpinned by expansion in Europe & Asia across (A$M) (A$M) (A$M) nutraceutical, food & beverage, and infant formula sectors. Revenue 86.0 62.2
Slide 8: Cash flow
Cash flow Reported Reported Movement 31 Jul 2025 31 Jul 2024 (A$M) (A$M) (A$M) For personal use only Cash receipts 74.8 60.7 +14.1 • Robust operating cash flows with higher trade Payments to suppliers & employees (64.6) (49.1) -15.5 receivables. Net interest paid (0.2) (0.9) +0.7 • Debt repayments r
Slide 9: Balance Sheet Highlights
Balance Sheet Highlights Reported Reported Movement 31 Jul 2025 31 Jul 2024 (A$M) (A$M) (A$M) For personal use only • Balance sheet strengthened, with net assets up Cash 8.7 12.2 -3.5 YoY, supported by higher NPAT and retained earnings. Trade receivables 25.1 13.7 +11.4 • Cash position remains healt
Slide 10: New products driving growth
For personal use only New products driving growth 10
Slide 11: CholineXcel
CholineXcel For personal use only • CholineXcel is a unique, flowable • Clover has applied for a global powder that overcomes current patent for CholineXcel significant challenges in handling technology. and stability in our customers’ • Customer-led product trials are manufacturing. on track to com
Slide 12: Premneo Adult & Infant Formula
Premneo Adult & Infant Formula Global infant formula market appears to have stabilised. For personal use only Growth driven by diversifying into non-allergenic formulations and enhanced fortification. Online sales in China increasing. DHA applications are expanding, with new growth opportunities in
Slide 13: Other products
Other products For personal use only Highly concentrated oils Gelphorm Probiotics Sales of powdered High Omega 3 Unique double emulsion DHA Probiotics are live organisms which in nutraceuticals, petfood and product that can pass through UHT quickly die when unfrozen. Food for Special Medical Purpose
Slide 14: Strategy and outlook
For personal use only Strategy and outlook 14
Slide 15: Strategy for growth
Strategy for growth For personal use only Accelerate commercialisation of new products Expand market reach Diversify into adjacent high-growth markets Deepen customer value and retention Clover Corp | Results Presentation September 2025 15
Slide 16: Outlook
Outlook For personal use only Based on the current market and global conditions, the Board expects 1H FY26 to be in line with 1H FY25. Clover Corp | Results Presentation September 2025 16
Slide 17: Why invest in Clover Corp?
Why invest in Clover Corp? Long-term supply Strong track record of For personal use only relationships with top-tier profitability, cash infant formula and food generation, and dividend manufacturers. payments. Approved supplier to Positioned for growth global multinationals with through innovation,
Slide 18: Global supply chain strength
Global supply chain strength Australia • Refinery in Melbourne, R&D facility in Brisbane • Site serves as both a manufacturing hub and R&D centre for the For personal use only company’s patented microencapsulation technologies. • Focusses on improving bioavailability, stability, and taste masking of
Slide 19: Board members
Board members For personal use only Rupert Harrington Peter Davey Toni Brendish Chair Managing Director & CEO Non-Executive Director Graeme Billings Dr. Simon Green Ian Glasson Fiona Pearse Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director 19
Slide 20: Q&A
For personal use only Q&A 20